ArticleJournal of medical virology2025
Dengue Virus Dynamic and Persistence in Body Fluids of Infected Patients in Italy, 2018-2023.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Dengue, a mosquito-borne disease caused by the dengue virus (DENV), is constantly expanding worldwide. We investigated the presence and persistence of DENV RNA in the bloodstream and other body fluids to describe the viral kinetics in the human host. We longitudinally collected serum (n = 118), plasma (n = 110), whole blood (n = 90), urine (n = 118), oral swabs (n = 68), saliva (n = 42), semen (n = 23), and vaginal fluids (n = 49) from 42 DENV patients. We measured DENV RNA for a median of 28 (range 1-63) days from symptom onset (DSO). We estimated the probability of viral detection applying a generalized linear model, and the duration of viremia using Monte Carlo-Markov Chain approach. In the bloodstream, the highest rate of positivity, levels of DENV RNA, and persistence were observed in whole blood. The estimated probability of a positive test dropped below 5% after 12.5, 20.7, and 35.4 DSO for plasma, serum, and whole blood, respectively. The average duration of viremia was estimated to be 19.9 DSO. Saliva and oral swabs showed 76.2% and 58.8% of DENV RNA positivity during the first week of symptoms while the longest persistence was observed in urine (39 DSO). DENV was revealed in 20% cervicovaginal (up to 11 DSO) and 30% seminal (up to 35 DSO) fluids. Whole blood represents the preferential specimen for dengue molecular detection and the correct estimation of viremia duration which have clear implications for onward transmission and public health countermeasures. Blood, urine, and oral samples can be assayed according to time from disease onset, severity, and screening purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.